Hopp til innhold
NHI.no
Annonse

Psoriasisgikt: Quiz

Innhold i artikkelen

Har du fått med deg det viktigste i dette dokumentet? Da utfordrer vi deg til å ta vår quiz om psoriasis!

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Psoriasisartritt . Referanselisten for dette dokumentet vises nedenfor

  1. Madland TM, Michelsen B, Hoff M, et al. Psoriasisartritt (PsA). Nasjonal veileder i revmatologi. Norsk reumatologisk forening. Publisert 09.02.2024, siden besøkt 28.03.24 metodebok.no
  2. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1-19. PubMed
  3. Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009 Feb;36(2):361-7. PubMed
  4. Scott IC, Whittle R, Bailey J, et al. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg Health Eur 2022. pmid:36246147 PubMed
  5. Kerola AM, Rollefstad S, Kazemi A, et al. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol. 2023;52(1):42-50. PMID: 35014920 PubMed
  6. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009; 11: 214. pmid:19232079 PubMed
  7. McLeod BD. Site of psoriasis (scalp or intergluteal/perianal), >or=3 affected sites, and nail dystrophy predicted psoriatic arthritis in incident psoriasis. Evid Based Med. 2009 Dec;14(6):185. PMID: 19949187. PubMed
  8. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73. pmid:16871531 PubMed
  9. D'Angelo S, Mennillo GA, Cutro MS, et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol 2009; 36: 368-70. pmid:19208566 PubMed
  10. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity?. Ann Rheum Dis 2005; 64: 188. pmid:15271771 PubMed
  11. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123. pmid:17216680 PubMed
  12. Villani AP,Rouzaud M,Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2015. PMID: 26054432 PubMed
  13. Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register, 2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):668-73. PubMed
  14. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006; 65: 478. pmid:16126794 PubMed
  15. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factorαtherapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382. pmid:21279995 PubMed
  16. Long V, Yew YW, Chandran NS, et al. Psoriasis flares and rebound phenomenon following exposure and withdrawal of systemic steroids: A systematic review and meta-analysis. J Am Acad Dermatol. 2022 Sep;87(3):660-661. Epub 2022 Jan 13. PMID: 35033606. pubmed.ncbi.nlm.nih.gov
  17. Olav Sundnes: Veiledende anbefalinger for systemisk behandling av psoriasis vulgaris, sept.2021, siden lest 23.03.24 www.legeforeningen.no
  18. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5. PubMed
  19. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4. PubMed
  20. Charlton R, Green A, Shaddick G, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis. 2017. PMID: 29092855 PubMed
  21. Guldberg-Møller J, Cordtz RL, Kristensen LE, Dreyer L. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. epub 215313. pmid:31300461 PubMed
  22. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74: 326-32. pmid:25351522 PubMed
  23. Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2019. pmid:31672774 PubMed
  24. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. PMID: 32434812 PubMed
  25. Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD012722. DOI: 10.1002/14651858.CD012722.pub2. DOI
Annonse
Annonse